Clinical ProtocolsTime FactorsRadiation DosageTreatment OutcomeLethal Dose 50Drug Administration ScheduleAdministration, OralRadiometryDouble-Blind MethodAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, RadiationResearch DesignDose FractionationRadiotherapy DosageInjections, IntravenousProspective StudiesReproducibility of ResultsInfusions, IntravenousArea Under CurveRadiotherapy Planning, Computer-AssistedDrug Therapy, CombinationHalf-LifeSensitivity and SpecificityRats, Sprague-DawleyRetrospective StudiesFollow-Up StudiesNeoplasmsFeasibility StudiesThermoluminescent DosimetryPregnancyAntineoplastic AgentsBody BurdenDisease Models, AnimalCombined Modality TherapyDrug InteractionsRats, WistarAnalysis of VariancePhantoms, ImagingAlgorithmsSingle-Blind MethodInjections, SubcutaneousRadiation InjuriesRandom AllocationDrug CombinationsRelative Biological EffectivenessClinical Trials as TopicTomography, X-Ray ComputedMetabolic Clearance RateDogsLiverBiological AvailabilityBlood PressureInjections, IntramuscularHeart RateDrug EvaluationRadiation MonitoringRadiotherapy, Intensity-ModulatedWireless TechnologyBody WeightRecombinant ProteinsMetered Dose InhalersCyclophosphamidePolymerase Chain ReactionOvulation InductionAntibodies, MonoclonalImmunosuppressive AgentsModels, BiologicalAdministration, InhalationInjections, IntraperitonealBrainKidneyMice, Inbred BALB CGonadotropin-Releasing HormonePlacebosChromatography, High Pressure LiquidSurvival AnalysisDoxorubicinIodine RadioisotopesCells, CulturedEquipment DesignPilot ProjectsPatient SelectionRecurrenceRandomized Controlled Trials as TopicRadioisotopesAnti-Bacterial AgentsMagnetic Resonance ImagingRisk FactorsInfant, NewbornRabbitsKineticsRisk AssessmentPain MeasurementOrgans at RiskMonte Carlo MethodRadiopharmaceuticalsLung NeoplasmsWhole-Body CountingSurvival RateLung